Abstract
Objective
Currently, it is unclear whether serum Cystatin C can be used to evaluate the prognosis of ALS. We aim to study the relationship between serum Cystatin C and survival in ALS.
Methods
Sporadic ALS patients diagnosed at the Department of Neurology, the First Medical Center, and the Chinese PLA General Hospital from January 2016 to December 2019 were enrolled in this study. Experienced neurologists followed up the participants regularly every 6 months until January 2022. According to the levels of serum Cystatin C, the participants were divided into high and low Cystatin C levels groups. The comparison between groups was performed with parametric or non-parametric test. Kaplan–Meier method and Cox regression model were used to calculate survival analysis.
Results
Three hundred fifty-six sporadic ALS patients were enrolled in this study, including 203 males and 153 females. Among all ALS patients, 26 cases (7.3%) were lost to follow-up, 226 cases (63.5%) died, and 104 cases (29.2%) were still alive at the last follow-up. The median survival time of all ALS patients was 42.0 months. Patients with high Cystatin C levels had shorter median survival than those with lower Cystatin C levels (38.0 months vs. 48.0 months, P = 2.58 × 10−4). In multivariate Cox regression analysis, onset form, age of onset, diagnostic delay, disease progression rate, creatinine, and serum Cystatin C levels were associated with ALS survival.
Conclusions
Our study found that serum Cystatin C was associated with ALS survival, and serum Cystatin C level might be an independent predictor of ALS survival.
Similar content being viewed by others
Data availability
The datasets generated during the current study are available from the corresponding author on reasonable request.
References
Logroscino G, Traynor BJ, Hardiman O et al (2008) Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 79(1):6–11
Guareschi S, Cova E, Cereda C et al (2012) An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc Natl Acad Sci U S A 109:5074–5079
Chen L, Zhang B, Chen R et al (2015) Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J Neurol Neurosurg Psychiatry 86(10):1075–1081
Kaufmann P, Levy G, Thompson JL et al (2005) The ALSFRSr predicts survival time in an ALS clinic population. Neurology 64(1):38–43
Wei Q, Chen X, Zheng Z et al (2015) The predictors of survival in Chinese amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 16(3–4):237–244
Filler G, Bökenkamp A, Hofmann W et al (2005) Cystatin C as a marker of GFR: history, indications, and future research. Clin Biochem 38(1):1–8
Gauthier S, Kaur G, Mi W et al (2011) Protective mechanisms by Cystatin C in neurodegenerative diseases. Front Biosci (Schol Ed) 3(2):541–554
Zi M, Xu Y (2018) Involvement of Cystatin C in immunity and apoptosis. Immunol Lett 196:80–90
Zhu Y, Yang M, Li F et al (2018) Aberrant levels of Cystatin C in amyotrophic lateral sclerosis: a systematic review and meta analysis. Int J Biol Sci 14(9):1041–1053
Ren Y, Zhu W, Cui F et al (2015) Measurement of Cystatin C levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Int J Clin Exp Pathol 8(5):5419–5426
Brooks BR, Miller RG, Swash M et al (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293–299
Pirttila TJ, Lukasiuk K, Hakansson K et al (2005) Cystatin C modulates neurodegeneration and neurogenesis following status epilepticus in mouse. Neurobiol Dis 20:241–253
Kaeser SA, Herzig MC, Coomaraswamy J et al (2007) Cystatin C modulates cerebral beta-amyloidosis. Nat Genet 39:1437–1439
Mi W, Pawlik M, Sastre M et al (2007) Cystatin C inhibits amyloid-beta deposition in Alzheimer’s disease mouse models. Nat Genet 39:1440–1442
Tizon B, Sahoo S, Yu H et al (2010) Induction of autophagy by Cystatin C: a mechanism that protects murine primary cortical neurons and neuronal cell lines. PLoS one 5:e9819
Mori F, Tanji K, Miki Y, Wakabayashi K (2009) Decreased Cystatin C immunoreactivity in spinal motor neurons and astrocytes in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 68:1200–1206
Nakanishi H (2003) Neuronal and microglial cathepsins in aging and age-related diseases. Ageing Res Rev 2:367–381
Wilson ME, Boumaza I, Lacomis D, Bowser R (2010) Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis. PLoS one 5:e15133
Imarisio A, Pilotto A, Garrafa E et al (2021) Plasma Cystatin C correlates with plasma NfL levels and predicts disease progression in Parkinson’s disease. Neurodegener Dis 21(5–6):109–116
Gaetani L, Blennow K, Calabresi P et al (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8):870–881
Ashton NJ, Janelidze S, Al Khleifat A et al (2021) A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun 12(1):3400
Benatar M, Zhang L, Wang L et al (2020) Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 95(1):e59–e69
Acknowledgements
We are grateful for all the participants who contributed to the study.
Author information
Authors and Affiliations
Contributions
Conceptualization: Xusheng Huang; Methodology: Yahui Zhu, Yunyun Huo, Jiongming Bai; formal analysis and investigation: Yahui Zhu, Yunyun Huo, Jiongming Bai, Mao Li, Hongfen Wang, Jiao Wang; writing—original draft preparation: Yahui Zhu; writing—review and editing: Xusheng Huang; Resources: Yahui Zhu; supervision: Xusheng Huang, Yahui Zhu, Yunyun Huo. All authors approved the version to be published.
Corresponding author
Ethics declarations
Ethical approval
This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Chinese PLA General Hospital.
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zhu, Y., Huo, Y., Bai, J. et al. Serum Cystatin C is a potential biomarker for predicting amyotrophic lateral sclerosis survival. Neurol Sci 45, 197–201 (2024). https://doi.org/10.1007/s10072-023-06957-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-023-06957-9